Photodynamic therapy with verteporfin for choroidal neovascularisations in clinical routine outside the TAP study. One- and two-year results including juxtafoveal and extrafoveal CNV

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 243, Issue 5, 2005, Pages 438-445

  Wachtlin, Joachim ^a   Stroux, Andrea ^a   Wehner, Andreas ^a   Heimann, Heinrich ^a   Foerster, Michael H ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE;

ADULT; AGED; ARTICLE; DIODE LASER; DISEASE SEVERITY; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; FUNCTIONAL ASSESSMENT; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; OUTCOMES RESEARCH; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA MACULA DEGENERATION; RISK FACTOR; STATISTICAL SIGNIFICANCE; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 20444459155     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-004-1071-z     Document Type: Article

References (18)

1. Axer-Siegel R, Ehrlich R, Yassur Y, Rosenblatt I, Kramer M, Priel E, Benjamini Y, Weinberger D (2004) Photodynamic therapy for age-related macular degeneration in a clinical setting: Visual results and angiographic patterns. Am J Ophthalmol 137(2):258-264
2. Barbazetto I, Burdan A, Bressler NM, Bressler SB, Haynes L, Kapetanios AD, Lukas J, Olsen K, Potter M, Reaves A, Rosenfeld P, Schachat AP, Strong HA, Wenkenstern A (2003) Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: Fluorescein angiographic guidelines for evaluation and treatment - TAP and VIP report no. 2. Arch Ophthalmol 121(9):1253-1268
3. Barnes RM, Gee L, Taylor S, Briggs MC, Harding SP (2004) Outcomes in verteporfin photodynamic therapy for choroidal neovascularisation - 'Beyond the TAP study'. Eye 18(8):809-813 10.1038/sj.eye.6701329
4. Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, Davis MD, de Jong PT, Klaver CC, Klein BE, Klein R, et al (1995) An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 39(5):367-374 1:STN:280:ByqA38fgsVQ%3D
5. Bressler NM (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP report 2. Arch Ophthalmol 119(2):198-207 11176980
6. Cohen SY, Bulik A, Dubois L, Quentel G (2003) Photodynamic therapy for juxtafoveal choroidal neovascularization in myopic eyes. Am J Ophthalmol 136(2):371-374 10.1016/S0002-9394(03)00201-0
7. Gelisken F, Inhoffen W, Hermann A, Grisanti S, Bartz-Schmidt KU (2004) Verteporfin photodynamic therapy for extrafoveal choroidal neovascularisation in pathologic myopia. Graefes Arch Clin Exp Ophthalmol
8. Macular Photocoagulation Study Group (1982) Argon laser photocoagulation for senile macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 100(6):912-918
9. Macular Photocoagulation Study Group (1986) Argon laser photocoagulation for neovascular maculopathy. Three-year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 104(5):694-701
10. Macular Photocoagulation Study Group (1990) Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol 108(6):816-824
11. Macular Photocoagulation Study Group (1991) Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study. Macular Photocoagulation Study Group. Arch Ophthalmol 109(9):1242-1257
12. Macular Photocoagulation Study Group (1994) Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 112(4):500-509
13. Schmidt-Erfurth U, Miller J, Sickenberg M, Bunse A, Laqua H, Gragoudas E, Zografos L, Birngruber R, van den Bergh H, Strong A, Manjuris U, Fsadni M, Lane AM, Piguet B, Bressler NM (1998) Photodynamic therapy of subfoveal choroidal neovascularization: Clinical and angiographic examples. Graefes Arch Clin Exp Ophthalmol 236(5):365-374
14. TAP Study Group (1999) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol 117(10):1329-1345
15. Verteporfin Roundtable 2000 and 2001 Participants (2002) Guidelines for using verteporfin (visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina 22(1):6-18
16. VIP Study Group (2003) Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial - VIP report no. 3. Ophthalmology 110(4):667-673
17. Wachtlin J, Heimann H, Behme T, Foerster MH (2003) Long-term results after photodynamic therapy with verteporfin for choroidal neovascularizations secondary to inflammatory chorioretinal diseases. Graefe Arch Clin Exp Ophthalmol 241:899-906
18. Wachtlin J, Wehner A, Heimann H, Foerster MH (2004) Photodynamic treatment with verteporfin for patients with idiopathic choroidal neovascularization: Two-year results. Ophthalmologe 101(5):489-495